Time Frame |
Active reporting period is from the time of informed consent until at least 28 days after study treatment last dose. For serious adverse events: those with the possibility of being related to study drug must be reported as minimum thereafter.
|
Adverse Event Reporting Description |
All causality (serious and non-serious) AEs
|
|
Arm/Group Title
|
Crizotinib 250 mg BID
|
Arm/Group Description |
Participants were administered criz...
|
Arm/Group Description |
Participants were administered crizotinib at a starting dose of 250 mg orally, BID on a continuous dosing period as two 100-mg tablets and one 50-mg tablet at approximately 12 hours apart the same time each day.
|
|
|
Crizotinib 250 mg BID
|
|
Affected / at Risk (%) |
Total |
--/-- |
|
|
Crizotinib 250 mg BID
|
|
Affected / at Risk (%) |
Total |
539/1066 (50.56%) |
Blood and lymphatic system disorders |
|
Anaemia |
4/1066 (0.38%) |
Basophilia |
1/1066 (0.09%) |
Eosinophilia |
1/1066 (0.09%) |
Febrile neutropenia |
6/1066 (0.56%) |
Leukocytosis |
1/1066 (0.09%) |
Monocytosis |
1/1066 (0.09%) |
Thrombocytopenia |
1/1066 (0.09%) |
Thrombocytosis |
1/1066 (0.09%) |
Cardiac disorders |
|
Acute myocardial infarction |
2/1066 (0.19%) |
Angina pectoris |
2/1066 (0.19%) |
Atrial fibrillation |
3/1066 (0.28%) |
Bradycardia |
1/1066 (0.09%) |
Cardiac arrest |
2/1066 (0.19%) |
Cardiac failure |
2/1066 (0.19%) |
Cardiac failure congestive |
1/1066 (0.09%) |
Cardiac tamponade |
1/1066 (0.09%) |
Coronary artery stenosis |
1/1066 (0.09%) |
Cyanosis |
1/1066 (0.09%) |
Left ventricular failure |
1/1066 (0.09%) |
Myocardial infarction |
2/1066 (0.19%) |
Myocarditis |
1/1066 (0.09%) |
Palpitations |
1/1066 (0.09%) |
Pericardial effusion |
7/1066 (0.66%) |
Pericarditis |
1/1066 (0.09%) |
Supraventricular tachycardia |
1/1066 (0.09%) |
Syncope |
6/1066 (0.56%) |
Tachycardia |
2/1066 (0.19%) |
Angina Unstable |
1/1066 (0.09%) |
Eye disorders |
|
Cataract |
2/1066 (0.19%) |
Glaucoma |
1/1066 (0.09%) |
Optic atrophy |
1/1066 (0.09%) |
Retinal detachment |
1/1066 (0.09%) |
Vision blurred |
1/1066 (0.09%) |
Vitreous haemorrhage |
1/1066 (0.09%) |
Gastrointestinal disorders |
|
Abdominal pain |
6/1066 (0.56%) |
Abdominal wall haematoma |
1/1066 (0.09%) |
Ascites |
1/1066 (0.09%) |
Colitis |
1/1066 (0.09%) |
Constipation |
3/1066 (0.28%) |
Diarrhoea |
4/1066 (0.38%) |
Diarrhoea haemorrhagic |
1/1066 (0.09%) |
Dysphagia |
7/1066 (0.66%) |
Gastric ulcer |
1/1066 (0.09%) |
Gastritis |
1/1066 (0.09%) |
Gastrointestinal haemorrhage |
3/1066 (0.28%) |
Ileus |
3/1066 (0.28%) |
Intestinal obstruction |
1/1066 (0.09%) |
Intestinal perforation |
1/1066 (0.09%) |
Nausea |
9/1066 (0.84%) |
Oesophageal stenosis |
1/1066 (0.09%) |
Oesophagitis |
2/1066 (0.19%) |
Pancreatic atrophy |
1/1066 (0.09%) |
Pancreatitis |
3/1066 (0.28%) |
Pancreatitis acute |
1/1066 (0.09%) |
Peptic ulcer haemorrhage |
1/1066 (0.09%) |
Peritoneal disorder |
1/1066 (0.09%) |
Retroperitoneal haemorrhage |
1/1066 (0.09%) |
Small intestinal obstruction |
1/1066 (0.09%) |
Subileus |
1/1066 (0.09%) |
Upper gastrointestinal haemorrhage |
1/1066 (0.09%) |
Vomiting |
6/1066 (0.56%) |
Rectal haemorrhage |
1/1066 (0.09%) |
General disorders |
|
Asthenia |
7/1066 (0.66%) |
Chest discomfort |
2/1066 (0.19%) |
Chest pain |
5/1066 (0.47%) |
Chills |
1/1066 (0.09%) |
Condition aggravated |
2/1066 (0.19%) |
Death |
8/1066 (0.75%) |
Device dislocation |
1/1066 (0.09%) |
Disease progression |
135/1066 (12.66%) |
Fatigue |
4/1066 (0.38%) |
Gait disturbance |
1/1066 (0.09%) |
General physical health deterioration |
9/1066 (0.84%) |
Generalised oedema |
3/1066 (0.28%) |
Mass |
1/1066 (0.09%) |
Multi-organ failure |
1/1066 (0.09%) |
Oedema peripheral |
7/1066 (0.66%) |
Pain |
1/1066 (0.09%) |
Pyrexia |
18/1066 (1.69%) |
Vascular stent thrombosis |
1/1066 (0.09%) |
Hepatobiliary disorders |
|
Cholecystitis |
1/1066 (0.09%) |
Drug-induced liver injury |
3/1066 (0.28%) |
Hepatic failure |
2/1066 (0.19%) |
Hepatitis |
1/1066 (0.09%) |
Hepatocellular injury |
1/1066 (0.09%) |
Hepatotoxicity |
3/1066 (0.28%) |
Immune system disorders |
|
Contrast media allergy |
1/1066 (0.09%) |
Infections and infestations |
|
Abdominal abscess |
1/1066 (0.09%) |
Abscess limb |
1/1066 (0.09%) |
Appendicitis |
8/1066 (0.75%) |
Bacteraemia |
2/1066 (0.19%) |
Bone abscess |
1/1066 (0.09%) |
Bronchitis |
2/1066 (0.19%) |
Candiduria |
1/1066 (0.09%) |
Cellulitis |
13/1066 (1.22%) |
Chest wall abscess |
1/1066 (0.09%) |
Clostridium difficile infection |
1/1066 (0.09%) |
Cystitis |
1/1066 (0.09%) |
Diverticulitis |
1/1066 (0.09%) |
Empyema |
1/1066 (0.09%) |
Gastroenteritis |
6/1066 (0.56%) |
Herpes zoster |
3/1066 (0.28%) |
Infection |
1/1066 (0.09%) |
Infectious pleural effusion |
2/1066 (0.19%) |
Infective spondylitis |
1/1066 (0.09%) |
Lower respiratory tract infection |
3/1066 (0.28%) |
Lung abscess |
1/1066 (0.09%) |
Lung infection |
14/1066 (1.31%) |
Meningitis |
1/1066 (0.09%) |
Metapneumovirus infection |
1/1066 (0.09%) |
Oesophageal candidiasis |
2/1066 (0.19%) |
Osteomyelitis chronic |
1/1066 (0.09%) |
Peritonitis |
1/1066 (0.09%) |
Pneumonia |
74/1066 (6.94%) |
Pneumonia bacterial |
1/1066 (0.09%) |
Pneumonia fungal |
1/1066 (0.09%) |
Pneumonia staphylococcal |
1/1066 (0.09%) |
Pyelonephritis |
1/1066 (0.09%) |
Renal abscess |
2/1066 (0.19%) |
Renal cyst infection |
2/1066 (0.19%) |
Respiratory tract infection |
5/1066 (0.47%) |
Sepsis |
8/1066 (0.75%) |
Septic shock |
4/1066 (0.38%) |
Skin infection |
4/1066 (0.38%) |
Soft tissue infection |
1/1066 (0.09%) |
Staphylococcal sepsis |
1/1066 (0.09%) |
Upper respiratory tract infection |
7/1066 (0.66%) |
Urinary tract infection |
7/1066 (0.66%) |
Urinary tract infection bacterial |
1/1066 (0.09%) |
Viral infection |
1/1066 (0.09%) |
Viral upper respiratory tract infection |
1/1066 (0.09%) |
Wound infection |
2/1066 (0.19%) |
Lymphangitis |
1/1066 (0.09%) |
Injury, poisoning and procedural complications |
|
Ankle fracture |
2/1066 (0.19%) |
Bone fissure |
1/1066 (0.09%) |
Dislocation of vertebra |
1/1066 (0.09%) |
Fall |
6/1066 (0.56%) |
Femoral neck fracture |
4/1066 (0.38%) |
Femur fracture |
4/1066 (0.38%) |
Hip fracture |
1/1066 (0.09%) |
Humerus fracture |
1/1066 (0.09%) |
Joint dislocation |
1/1066 (0.09%) |
Lower limb fracture |
1/1066 (0.09%) |
Overdose |
1/1066 (0.09%) |
Pelvic fracture |
1/1066 (0.09%) |
Radiation necrosis |
1/1066 (0.09%) |
Radiation pneumonitis |
1/1066 (0.09%) |
Radius fracture |
2/1066 (0.19%) |
Road traffic accident |
2/1066 (0.19%) |
Spinal compression fracture |
2/1066 (0.19%) |
Subdural haemorrhage |
1/1066 (0.09%) |
Traumatic haematoma |
1/1066 (0.09%) |
Upper limb fracture |
1/1066 (0.09%) |
Craniocerebral injury |
1/1066 (0.09%) |
Postoperative wound complication |
1/1066 (0.09%) |
Wound dehiscence |
1/1066 (0.09%) |
Investigations |
|
Alanine aminotransferase increased |
5/1066 (0.47%) |
Blood albumin decreased |
1/1066 (0.09%) |
Blood bilirubin increased |
1/1066 (0.09%) |
Blood creatinine increased |
1/1066 (0.09%) |
Blood lactate dehydrogenase increased |
1/1066 (0.09%) |
C-reactive protein increased |
1/1066 (0.09%) |
Electrocardiogram QT prolonged |
1/1066 (0.09%) |
Hepatic enzyme increased |
1/1066 (0.09%) |
Troponin I increased |
1/1066 (0.09%) |
Metabolism and nutrition disorders |
|
Decreased appetite |
3/1066 (0.28%) |
Dehydration |
4/1066 (0.38%) |
Failure to thrive |
2/1066 (0.19%) |
Fluid retention |
1/1066 (0.09%) |
Hypercalcaemia |
1/1066 (0.09%) |
Hyperglycaemia |
2/1066 (0.19%) |
Hyperkalaemia |
1/1066 (0.09%) |
Hypoalbuminaemia |
1/1066 (0.09%) |
Hypocalcaemia |
1/1066 (0.09%) |
Hypoglycaemia |
1/1066 (0.09%) |
Hypokalaemia |
5/1066 (0.47%) |
Hypomagnesaemia |
1/1066 (0.09%) |
Hyponatraemia |
4/1066 (0.38%) |
Hypophosphataemia |
1/1066 (0.09%) |
Musculoskeletal and connective tissue disorders |
|
Arthralgia |
2/1066 (0.19%) |
Back pain |
5/1066 (0.47%) |
Bursitis |
1/1066 (0.09%) |
Chest wall mass |
1/1066 (0.09%) |
Joint swelling |
1/1066 (0.09%) |
Lumbar spinal stenosis |
1/1066 (0.09%) |
Muscular weakness |
2/1066 (0.19%) |
Musculoskeletal pain |
3/1066 (0.28%) |
Myalgia |
1/1066 (0.09%) |
Myopathy |
1/1066 (0.09%) |
Neck pain |
2/1066 (0.19%) |
Osteoarthritis |
1/1066 (0.09%) |
Pain in extremity |
2/1066 (0.19%) |
Pathological fracture |
5/1066 (0.47%) |
Spinal column stenosis |
1/1066 (0.09%) |
Spondylolisthesis |
1/1066 (0.09%) |
Systemic lupus erythematosus |
1/1066 (0.09%) |
Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
Basal cell carcinoma |
1/1066 (0.09%) |
Breast cancer |
1/1066 (0.09%) |
Gallbladder cancer |
1/1066 (0.09%) |
Malignant melanoma |
2/1066 (0.19%) |
Metastases to meninges |
1/1066 (0.09%) |
Neoplasm malignant |
1/1066 (0.09%) |
Neuroendocrine tumour |
1/1066 (0.09%) |
Plasma cell myeloma |
1/1066 (0.09%) |
Prostate cancer |
1/1066 (0.09%) |
Small cell lung cancer |
1/1066 (0.09%) |
Squamous cell carcinoma of skin |
2/1066 (0.19%) |
Nervous system disorders |
|
Aphasia |
2/1066 (0.19%) |
Ataxia |
1/1066 (0.09%) |
Brain oedema |
3/1066 (0.28%) |
Cerebellar infarction |
1/1066 (0.09%) |
Cerebral haemorrhage |
4/1066 (0.38%) |
Cerebral infarction |
1/1066 (0.09%) |
Cerebrovascular accident |
1/1066 (0.09%) |
Chorea |
1/1066 (0.09%) |
Coma |
1/1066 (0.09%) |
Depressed level of consciousness |
1/1066 (0.09%) |
Dizziness |
2/1066 (0.19%) |
Dysarthria |
2/1066 (0.19%) |
Generalised tonic-clonic seizure |
1/1066 (0.09%) |
Haemorrhage intracranial |
1/1066 (0.09%) |
Headache |
4/1066 (0.38%) |
Intracranial pressure increased |
1/1066 (0.09%) |
Ischaemic stroke |
1/1066 (0.09%) |
Nervous system disorder |
2/1066 (0.19%) |
Neurological decompensation |
1/1066 (0.09%) |
Paraplegia |
1/1066 (0.09%) |
Peripheral motor neuropathy |
1/1066 (0.09%) |
Peripheral sensorimotor neuropathy |
1/1066 (0.09%) |
Peripheral sensory neuropathy |
1/1066 (0.09%) |
Pyramidal tract syndrome |
1/1066 (0.09%) |
Seizure |
9/1066 (0.84%) |
Spinal cord compression |
2/1066 (0.19%) |
Transient ischaemic attack |
3/1066 (0.28%) |
Tremor |
1/1066 (0.09%) |
Vocal cord paralysis |
2/1066 (0.19%) |
Psychiatric disorders |
|
Completed suicide |
1/1066 (0.09%) |
Confusional state |
7/1066 (0.66%) |
Depression |
3/1066 (0.28%) |
Disorientation |
1/1066 (0.09%) |
Mania |
1/1066 (0.09%) |
Mental status changes |
2/1066 (0.19%) |
Suicide attempt |
1/1066 (0.09%) |
Renal and urinary disorders |
|
Acute kidney injury |
5/1066 (0.47%) |
Dysuria |
2/1066 (0.19%) |
Haematuria |
1/1066 (0.09%) |
Hydronephrosis |
2/1066 (0.19%) |
Nephrolithiasis |
2/1066 (0.19%) |
Renal cyst |
13/1066 (1.22%) |
Renal cyst haemorrhage |
1/1066 (0.09%) |
Renal failure |
1/1066 (0.09%) |
Ureteral polyp |
1/1066 (0.09%) |
Urinary retention |
2/1066 (0.19%) |
Urinary tract obstruction |
1/1066 (0.09%) |
Reproductive system and breast disorders |
|
Benign prostatic hyperplasia |
1/1066 (0.09%) |
Pelvic pain |
1/1066 (0.09%) |
Respiratory, thoracic and mediastinal disorders |
|
Acute respiratory distress syndrome |
1/1066 (0.09%) |
Acute respiratory failure |
3/1066 (0.28%) |
Alveolitis |
1/1066 (0.09%) |
Asphyxia |
1/1066 (0.09%) |
Atelectasis |
1/1066 (0.09%) |
Bronchial hyperreactivity |
1/1066 (0.09%) |
Chronic obstructive pulmonary disease |
1/1066 (0.09%) |
Cough |
3/1066 (0.28%) |
Dyspnoea |
39/1066 (3.66%) |
Epistaxis |
1/1066 (0.09%) |
Haemoptysis |
3/1066 (0.28%) |
Hypoxia |
4/1066 (0.38%) |
Interstitial lung disease |
5/1066 (0.47%) |
Lung infiltration |
1/1066 (0.09%) |
Oropharyngeal pain |
1/1066 (0.09%) |
Pleural effusion |
14/1066 (1.31%) |
Pleuritic pain |
1/1066 (0.09%) |
Pneumonia aspiration |
4/1066 (0.38%) |
Pneumonitis |
17/1066 (1.59%) |
Pneumothorax |
8/1066 (0.75%) |
Pulmonary arterial hypertension |
1/1066 (0.09%) |
Pulmonary artery thrombosis |
2/1066 (0.19%) |
Pulmonary embolism |
26/1066 (2.44%) |
Pulmonary haemorrhage |
1/1066 (0.09%) |
Pulmonary oedema |
1/1066 (0.09%) |
Pulmonary thrombosis |
1/1066 (0.09%) |
Rales |
2/1066 (0.19%) |
Respiratory failure |
17/1066 (1.59%) |
Haemothorax |
1/1066 (0.09%) |
Skin and subcutaneous tissue disorders |
|
Paraneoplastic pemphigus |
1/1066 (0.09%) |
Rash |
1/1066 (0.09%) |
Surgical and medical procedures |
|
Pleural decortication |
1/1066 (0.09%) |
Vascular disorders |
|
Deep vein thrombosis |
14/1066 (1.31%) |
Embolism |
1/1066 (0.09%) |
Haematoma |
3/1066 (0.28%) |
Hypotension |
1/1066 (0.09%) |
Hypovolaemic shock |
1/1066 (0.09%) |
Orthostatic hypotension |
1/1066 (0.09%) |
Peripheral arterial occlusive disease |
1/1066 (0.09%) |
Peripheral embolism |
2/1066 (0.19%) |
Phlebitis |
1/1066 (0.09%) |
Superior vena cava syndrome |
4/1066 (0.38%) |
Thrombophlebitis |
1/1066 (0.09%) |
Thrombosis |
5/1066 (0.47%) |
Vasculitis |
1/1066 (0.09%) |
Vena cava thrombosis |
2/1066 (0.19%) |
Venous thrombosis |
4/1066 (0.38%) |
Indicates events were collected by non-systematic assessment
Term from vocabulary, MedDRA (v18.1)
|
|
Frequency Threshold for Reporting Other Adverse Events
|
5%
|
|
Crizotinib 250 mg BID
|
|
Affected / at Risk (%) |
Total |
1038/1066 (97.37%) |
Blood and lymphatic system disorders |
|
Anaemia |
138/1066 (12.95%) |
Leukopenia |
101/1066 (9.47%) |
Lymphopenia |
71/1066 (6.66%) |
Neutropenia |
180/1066 (16.89%) |
Cardiac disorders |
|
Bradycardia |
93/1006 (9.24%) |
Eye disorders |
|
Photopsia |
96/1066 (9.01%) |
Vision blurred |
80/1066 (7.50%) |
Visual impairment |
460/1066 (43.15%) |
Gastrointestinal disorders |
|
Abdominal pain |
118/1066 (11.07%) |
Abdominal pain upper |
106/1066 (9.94%) |
Constipation |
475/1066 (44.56%) |
Diarrhoea |
548/1066 (51.41%) |
Dyspepsia |
81/1066 (7.60%) |
Dysphagia |
56/1066 (5.25%) |
Nausea |
603/1066 (56.57%) |
Vomiting |
565/1066 (53.00%) |
General disorders |
|
Asthenia |
156/1066 (14.63%) |
Chest pain |
105/1066 (9.85%) |
Fatigue |
326/1066 (30.58%) |
Oedema |
96/1066 (9.01%) |
Oedema peripheral |
450/1066 (42.21%) |
Pyrexia |
181/1066 (16.98%) |
Infections and infestations |
|
Nasopharyngitis |
113/1066 (10.60%) |
Upper respiratory tract infection |
145/1066 (13.60%) |
Urinary tract infection |
62/1066 (5.82%) |
Injury, poisoning and procedural complications |
|
Fall |
59/1066 (5.53%) |
Investigations |
|
Alanine aminotransferase increased |
302/1006 (30.02%) |
Aspartate aminotransferase increased |
233/1006 (23.16%) |
Blood alkaline phosphatase increased |
76/1006 (7.55%) |
Blood creatinine increased |
105/1006 (10.44%) |
Blood lactate dehydrogenase increased |
60/1006 (5.96%) |
Neutrophil count decreased |
84/1066 (7.88%) |
Weight decreased |
109/1066 (10.23%) |
Weight increased |
98/1066 (9.19%) |
White blood cell count decreased |
98/1006 (9.74%) |
Metabolism and nutrition disorders |
|
Decreased appetite |
326/1066 (30.58%) |
Hyperglycaemia |
55/1066 (5.16%) |
Hypoalbuminaemia |
98/1066 (9.19%) |
Hypocalcaemia |
99/1066 (9.29%) |
Hypokalaemia |
77/1066 (7.22%) |
Hyponatraemia |
54/1066 (5.07%) |
Musculoskeletal and connective tissue disorders |
|
Arthralgia |
131/1066 (12.29%) |
Back pain |
184/1066 (17.26%) |
Muscle spasms |
79/1066 (7.41%) |
Muscular weakness |
57/1066 (5.35%) |
Pain in extremity |
137/1066 (12.85%) |
Musculoskeletal pain |
74/1066 (6.94%) |
Nervous system disorders |
|
Dizziness |
265/1066 (24.86%) |
Dysgeusia |
213/1066 (19.98%) |
Headache |
214/1066 (20.08%) |
Hypoaesthesia |
65/1066 (6.10%) |
Paraesthesia |
83/1066 (7.79%) |
Psychiatric disorders |
|
Anxiety |
76/1066 (7.13%) |
Insomnia |
136/1066 (12.76%) |
Respiratory, thoracic and mediastinal disorders |
|
Cough |
260/1066 (24.39%) |
Dyspnoea |
224/1066 (21.01%) |
Haemoptysis |
55/1066 (5.16%) |
Oropharyngeal pain |
75/1066 (7.04%) |
Productive cough |
71/1066 (6.66%) |
Skin and subcutaneous tissue disorders |
|
Alopecia |
67/1066 (6.29%) |
Pruritus |
84/1066 (7.88%) |
Rash |
134/1066 (12.57%) |
Indicates events were collected by non-systematic assessment
Term from vocabulary, MedDRA (v18.1)
|